63 results about "Pancreatitides" patented technology

The invention relates to the technical field of medical biology, in particular to a chronic pancreatitis complication risk grading system based on exosome transcriptome data, and aims to solve the problems that existing chronic pancreatitis (CP) typing lacks molecular basis, complication risk prediction is weak and clinical transformation is poor. According to the system, plasma exosomes are extracted and sequenced, a functional characteristic gene set is constructed in combination with pancreas single cell data, CP is divided into three risk increasing subtypes by using a COCA algorithm, and finally 12 core miRNAs are screened to construct a BPNN diagnosis model. The invention proves that the plasma exosome can be used for staging classification of chronic pancreatitis for the first time, miRNA non-invasive accurate layering illness conditions can be detected through qPCR, the risk of fatty diarrhea and 3c type diabetes mellitus can be predicted, and the non-invasiveness, convenience, classification accuracy and result repeatability of the plasma exosome have clinical application and transformation advantages.

The application belongs to the technical field of medicine, and relates to a compound composition, a preparation method and application, in particular to a compound sodium salicylate composition for treating acute pancreatitis and a preparation method. The compound sodium salicylate composition comprises quercetin, diammonium glycyrrhizinate and sodium salicylate, wherein the mass ratio of quercetin, diammonium glycyrrhizinate and sodium salicylate is 1-5:5-20:50-200. When the compound sodium salicylate composition is an injection, it comprises quercetin, diammonium glycyrrhizinate, sodium salicylate, 1,2-propanediol, sodium bisulfite, dimethyl sulfoxide and 0.9% sodium chloride injection. The volume ratio of 1,2-propanediol and dimethyl sulfoxide in the injection is 14-20% and 0.25-1% respectively; and the mass / volume ratio of sodium bisulfite in the injection is 0.1-0.3%. The compound sodium salicylate composition can significantly reduce amylase, lipase, IL-6 and IL-1beta, and can be used for preparing a medicine for treating pancreatitis.

The invention provides a marker combination for predicting severe acute pancreatitis and application thereof. Specifically, the invention provides application of a gene, mRNA, cDNA and protein of a risk marker for judging severe acute pancreatitis or a detection reagent of the gene, the mRNA, the cDNA and the protein, and the gene, the mRNA, the cDNA and the protein are used for preparing / establishing a diagnostic reagent or a kit / equipment for judging the occurrence risk of severe acute pancreatitis. Researches show that the severe acute pancreatitis risk marker can be used as a marker for early judgment of whether acute pancreatitis patients develop into severe acute pancreatitis, has high sensitivity and specificity, can quickly diagnose severe acute pancreatitis at a relatively early disease progress stage, and provides powerful assistance for early treatment intervention of diseases.

The invention discloses an external application medicine formula for acute pancreatitis, and belongs to the field of traditional Chinese medicine preparation formulas, and the external application medicine formula for acute pancreatitis is prepared from the following raw materials in parts by weight: 1-2 parts of honeysuckle, 1-2 parts of wild chrysanthemum flower, 1-2 parts of dandelion, 1-2 parts of herba violae, 1 part of scutellaria baicalensis, 1 part of coptis chinensis, 1 part of raw rhubarb, 1 part of raw liquorice, 1 part of radix paeoniae rubra and 1 part of mangnolia officinalis. The traditional Chinese medicine composition can effectively reduce peripancreatic exudation and promote gastrointestinal motility, so that the symptoms of abdominal distension and abdominal pain of a patient are relieved, meanwhile, pancreatic microcirculation can be improved, disease recovery is facilitated, the preparation process is simple and easy to understand, complex equipment is not needed, and the production cost is greatly reduced.

The invention discloses a si-TGM2-loaded macrophage targeting nano-material as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims at solving the problem that a macrophage targeting nano-drug for inhibiting severe acute pancreatitis aiming at a TGM2 target is lacked in the prior art. The technical key points of the invention are as follows: the si-TGM2-loaded macrophage targeting nano material is provided, the si-TGM2-loaded macrophage targeting nano material is a lactoferrin modified cationic lipid nucleic acid drug, and the cationic lipid nucleic acid drug is prepared by coating si-TGM2 as shown in SEQ.ID. NO.1 with a cationic liposome. The si-TGM2-loaded macrophage targeting nanometer material disclosed by the invention has a wide application prospect in preparation of an acute pancreatitis diagnostic kit and a medicine.

The invention discloses an acute necrotizing pancreatitis severe prediction model construction method based on a machine learning method. The acute necrotizing pancreatitis severe prediction model construction method comprises the following steps: S1, collecting patient data based on an inclusion standard and an exclusion standard; s2, data preprocessing and feature selection; s3, obtaining an optimal differential diagnosis prediction model in combination with radiomics characteristics and a plurality of machine learning algorithms; s4, obtaining an evaluation index through prediction performance comparison; and S5, constructing a pancreas model, a pancreas surrounding model and a combination model, and producing an ROC curve interpretation result. The present invention develops and verifies a machine learning model for distinguishing between severe and moderate ANPs (i.e., ANSP and ANMSP). These models will be based on radiomics features extracted from pancreatic parenchyma portal vein phase CECT images, peripancreatic necrotic lesions, and combinations thereof. By evaluating the diagnostic performance of the models, early recognition of disease severity is realized, and support is provided for clinical decisions related to treatment.

1. Name of the product in this design: Playing cards (Diet for patients with hyperlipidemia and pancreatitis). 2. Purpose of this design: For use in playing card entertainment products. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design highlights: Component 1 main view. 5. The design for which protection is sought includes color. 6. This design is for a thin product, and the left, right, top, and bottom views of components 1 to 54 are omitted.

Disclosed herein are compositions and methods for improving pancreatitis through pharmacological manipulation of calcium signaling. Such compositions and methods can be used to improve symptoms of acute or chronic pancreatitis or to reduce the likelihood or severity of pancreatitis in individuals at risk for the condition. In other embodiments, disclosed herein are compositions and methods for improving viral disease through pharmacological manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods for improving Thl7-induced disease through pharmacological manipulation of calcium signaling.

The invention relates to an autoimmune pancreatitis treatment response evaluation system based on sequence image change. The system comprises the following steps: preprocessing a CT pancreatic image and an MRI pancreatic image to obtain preprocessed pancreatic image data; extracting multi-scale features of the preprocessed pancreatic image data; fusing and reconstructing the CT pancreatic image and the MRI pancreatic image by using the multi-scale features to obtain a fused feature image; and inputting the fused feature image as a training sample into a deep learning model for training to obtain a pancreatitis treatment response evaluation model so as to complete prediction of the treatment response of the target pancreatitis patient. According to the method, image data of CT and MRI in two different modes are combined, the defects of a single image mode can be overcome, more comprehensive and accurate focus information can be provided, the lesion area of the pancreas can be better presented after the CT and the MRI are combined, and especially in dynamic observation of lump changes in the treatment process, the pancreatic lesion area can be more accurately observed. And the reaction condition of pancreatitis can be evaluated more accurately.

The application discloses application of an HTRA1 inhibitor in preparation of a drug for treating pancreatitis-cancer transformation, and belongs to the technical field of medicines.The HTRA1 inhibitor is screened through a drug database, the HTRA1 inhibitor is used to treat a pancreatic cancer cell line and a mouse pancreatitis-cancer transformation in-vivo model, it is proved that the HTRA1 inhibitor Carfilzomib can inhibit the malignant phenotype of Panc1 cells in vitro, and can inhibit the transformation of a KC mouse stimulated by cerulean into a pancreatic ductal adenocarcinoma in vivo, and the application provides a basis for using the HTRA1 inhibitor as the drug for treating pancreatitis-cancer transformation.

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and / or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.

Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.

Aspects of the present application provide dual inhibitor antitrypsin 1 / trypsin 2 antibodies and methods of using the antibodies to treat pancreatitis.

The invention provides a rheum officinale active ingredient composition as well as a preparation method and application thereof, and the active ingredients of the composition consist of emodin methyl ether glycoside, rhein, rhein, gallic acid, emodin and chrysophanol glycoside. The weight ratio of physcion glycoside to rhein glycoside to rhein to gallic acid to emodin to chrysophanol glycoside is 200: 100: 20: 10: 1: 1, the composition is prepared in a monomer mixing mode, the pancreatitis focus area is remarkably reduced, the pathological score is remarkably improved, and the serum amylase and lipase level is remarkably reduced; a certain liver protection effect is achieved; the components are clear in material basis, have no obvious liver and kidney toxicity, and can obviously improve and treat pancreatitis.

This invention discloses the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating acute respiratory distress syndrome (ARDS) induced by severe acute pancreatitis, belonging to the field of nanomedicine technology. This invention is the first to propose the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating ARDS induced by severe acute pancreatitis, providing a new method for treating ARDS and expanding the application of rhubarb-derived exosome-like nanovesicles in the pharmaceutical field. This invention is also the first to propose using rhubarb-derived exosome-like nanovesicles as the active ingredient in a pharmaceutical composition for treating ARDS induced by severe acute pancreatitis.

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

The present application belongs to the technical field of enteral nutrition preparation, and particularly relates to an enteral nutrition supplement for hyperlipidemia, a preparation method and application thereof. The enteral nutrition supplement comprises the following raw materials: medium-chain triglyceride, camellia chrysanthemum culture and cherry blossom polyphenol, and further comprises protein 15-25 parts, carbohydrate 40-50 parts, compound vitamin 0.01-0.05 parts and mineral 1-5 parts. The prepared enteral nutrition supplement is composed of a fat system completely formed by medium-chain fatty acid ester, and the blood fat is improved by synergistic effect of the camellia chrysanthemum culture and the cherry blossom polyphenol, so as to solve the application problem of traditional long-chain fat nutrition support under specific pathological conditions such as fatty liver, chylous fistula and chronic pancreatitis.

Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.

The invention relates to application of an FAK inhibitor in preparation of a medicine for preventing or treating acute pancreatitis. The FAK inhibitor is Defaciyinib, and the application concentration of the Defaciyinib in a mouse body is 4 mg / kg. The invention further provides a medicine, and the active ingredient of the medicine is Defaciyinib. It is found for the first time that the FAK inhibitor Defaciyinib can serve as the ferroptosis inhibitor to be applied to preparation of the medicine for preventing or treating acute pancreatitis, it is proved through western blot and real-time fluorescent quantitative PCR detection that Defaciyinib can inhibit expression of ferroptosis related genes and inhibit generation of intracellular lipid reactive oxygen, safety is high, and the FAK inhibitor Defaciyinib can be used for preparing the medicine for preventing or treating acute pancreatitis. Therefore, the compound can be used as a ferroptosis inhibitor to be applied to preparation of drugs for preventing or treating acute pancreatitis, and a new means is provided for disease treatment.

The present application relates to the use of an Axl agonist, a Mertk agonist, a CCR5 inhibitor or a CD22 inhibitor in the prevention or treatment of severe acute pancreatitis (SAP).

The application provides a diagnostic biomarker for identifying IgG4-related pancreatitis and pancreatic cancer and an application thereof, and the diagnostic biomarker is used in the preparation of a detection reagent for diagnosing IgG4-related pancreatitis and pancreatic cancer. By detecting the diagnostic biomarker, it can be identified whether it is IgG4-related pancreatitis or pancreatic cancer, and the operation is convenient, practical, and has good application value.

The application discloses Bifidobacterium breve and application of exopolysaccharide produced by the Bifidobacterium breve in prevention and treatment of hyperlipidemia acute pancreatitis, and belongs to the technical field of biological medicine. The application screens a Bifidobacterium breve with high yield of glucuronan exopolysaccharide, and the strain or the exopolysaccharide produced by the strain can help to reduce hyperlipidemia acute pancreatitis and reduce pancreatic lipid metabolism and inflammatory injury caused by HTG-AP.

The application discloses a PET-CT-based automatic auxiliary diagnosis method for pancreatic cancer and autoimmune pancreatitis, which comprises the following steps: image preprocessing is performed on PET images and CT images respectively; based on a Faster-Rcnn algorithm, an attention mechanism module is introduced into a residual network of Resnet50, an FPN network is added to form a feature pyramid network, and an ROIAlign is used to replace an ROIPooling layer, an improved detection network is constructed, target detection is performed on the image-preprocessed PET images and CT images respectively, and a lesion detection result is output 18 F-FDG PET / CT images; a hybrid classification model is constructed, imageomics feature extraction and deep learning feature extraction are performed on the F-FDG PET / CT images, multi-modal feature fusion, multi-domain feature fusion and feature correlation analysis are performed, and a lesion classification result is output. 18 F-FDG PET / CT images; a hybrid classification model is constructed, imageomics feature extraction and deep learning feature extraction are performed on the F-FDG PET / CT images, multi-modal feature fusion, multi-domain feature fusion and feature correlation analysis are performed, and a lesion classification result is output.

The invention discloses an acute pancreatitis research-oriented gene data priority transmission method and device, and solves the problem that the integrity is easily damaged due to resource competition in acute pancreatitis gene data transmission. The method comprises the following steps: constructing a physical isolation dual-channel architecture comprising a general data transmission channel and a special transmission channel on a network interface card hardware layer; analyzing the data downloading request, identifying a target gene data set based on predefined acute pancreatitis disease associated features, and scheduling the target gene data set to a special transmission channel; reserving bandwidth and buffer area resources for the gene data set, and implementing uncompressed straight-through transmission; real-time integrity verification is carried out on the data packet in the transmission process, a retransmission mechanism is triggered when verification fails, and if retransmission attempts fail for multiple times, a degradation transmission mechanism is started to route the data packet to a general data transmission channel; and recording a structured log after transmission is completed. And through hardware-level isolation and priority scheduling, the consistency and traceability of data delivery are improved.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The present application relates to the field of medicine, and particularly relates to a liposome loaded with phagolysosomal peptide, a preparation method and application thereof, so as to provide a drug for treating pancreatitis, and meanwhile improve the bioavailability of the drug. The liposome loaded with phagolysosomal peptide comprises phagolysosomal peptide and a shell coated on the periphery of the phagolysosomal peptide, the shell comprises an inner layer and an outer layer, the shell component is distearoyl phosphatidyl ethanolamine-polyethylene glycol, and there is a selenium-selenium bond between the inner layer and the outer layer. The inventor of the present application first discloses the direct effect and mechanism of the phagolysosomal peptide on the damaged pancreas of SAP, and the prepared DSSM@TN liposome can inhibit P2X7-induced mitochondrial damage, accumulation of ROS and expression of NLRP3, improve the bioavailability of the phagolysosomal peptide, significantly enhance the efficacy of the phagolysosomal peptide, and further improve the potential of the phagolysosomal peptide in preventing and treating SAP in the clinic. The DSSM@TN liposome can be used as a drug for treating pancreatitis, and meanwhile provides a new direction for the treatment research of pancreatitis.

The present invention relates to the field of pharmaceutical technology, and particularly, to a pirfenidone co-crystal and a method for preparing same, a pharmaceutical composition, and use thereof. The pirfenidone co-crystal provided in the present invention is prepared from pirfenidone and a co-crystal ligand selected from one of pimelic acid, cinnamic acid, and saccharin. The pirfenidone co-crystal provided in the present invention can not only improve the effect of pirfenidone in relieving acute pancreatitis, but also improve the safety of pirfenidone.

The application discloses a medicine for treating pancreatitis and a preparation method thereof, and the medicine contains astragaloside and calycosin-7-glucoside as active ingredients, and the weight ratio of the astragaloside and the calycosin-7-glucoside is 1-2:4-7. The astragaloside and the calycosin-7-glucoside are extracted from traditional Chinese medicine components through a large number of tests, and the combination of the two in a certain proportion has a good effect on treating acute pancreatitis, has no toxic side effect and is low in cost.